Vous avez cherché: viable treatment (Danois - Estonien)

modificeret »gold treatment«
modifitseeritud kullakäsitlus

treatment outcomes index).
ravivastuse indeks) ei täheldatud kasu, mida võiks omistada betaferoni’ le.

feltet "treatment, standards, routes"
nimeväli „töötlus, standardid, tootmisviisid”

detoxifying agents for antineoplastic treatment, atc- kode:
detoksifitseerivad ained tsütostaatiliseks raviks, atc- kood:

clinicoimmunologic aspects of botulinum toxin type b treatment of cervical dystonia.
clinicoimmunologic aspects of botulinum toxin type b treatment of cervical dystonia.

patientandel (%) med bevist/ sandsynlig ifis on- treatment periodeb 1899d
tõestatud/ tõenäoliste invasiivsete seeninfektsioonidega patsientide osakaal (%) raviperioodb 1899d 316e

patientandel (%) med bevist/ sandsynlig aspergillosis on- treatment periodeb 1899d 316e
tõestatud/ tõenäolise invasiivsete aspergilloosiga patsientide osakaal (%) raviperioodb 1899d 316e

according to the complainant, the settlement signed with bt in 1995 gives the incumbent preferential treatment.
according to the complainant, the settlement signed with bt in 1995 gives the incumbent preferential treatment.

»market survey on pm reduction after-treatment devices«, marts 2007.
„turu-uuring tahkete osakeste vähendamiseks ettenähtud järeltöötlusseadmete kohta”, märts 2007.

analysen af progressionsfri overlevelse on- treatment bekræftede dog ikke resultaterne fra den generelle progressionsfri overlevelse og samlede overlevelse:
kuid raviaegne progressioonivaba elulemuse analüüs ei kinnitanud üldise progressioonivaba elulemuse ja üldise elulemuse analüüsi tulemusi:

hiv/aids strategies must be designed to address the constraints that make it difficult for girls to use prevention tools, treatment and care services.
hiv/aids strategies must be designed to address the constraints that make it difficult for girls to use prevention tools, treatment and care services.

the preferential tax treatment does not seem to be related to investment or to job creation and constitutes a permanent relief from charges that should be normally met by these companies in the course of their business.
the preferential tax treatment does not seem to be related to investment or to job creation and constitutes a permanent relief from charges that should be normally met by these companies in the course of their business.

even if the use of different methods and revision mechanisms would be based on an objective set of criteria, the commission would expect these different methods to ensure equal treatment by yielding comparable results.
even if the use of different methods and revision mechanisms would be based on an objective set of criteria, the commission would expect these different methods to ensure equal treatment by yielding comparable results.

once- daily fleroxacin versus twice- daily ciprofloxacin in the treatment of complicated urinary tract infectionsj urol 1997; 158:
once- daily fleroxacin versus twice- daily ciprofloxacin in the treatment of complicated urinary tract infections j urol 1997; 158:

settlement of payment orders in the queue ( 1 ) the treatment of payment orders placed in queues depends on the priority class to which it was designated by the instructing participant .
settlement of payment orders in the queue ( 1 ) the treatment of payment orders placed in queues depends on the priority class to which it was designated by the instructing participant .

[10] however, these plans have been postponed at least until 2009, apparently because of difficulties in finding viable solutions for replacing the levy income with commercial revenues.
[10] however, these plans have been postponed at least until 2009, apparently because of difficulties in finding viable solutions for replacing the levy income with commercial revenues.

this statement appears to be incompatible with the commission's position in previous fiscal aid cases stipulating that nothing justified preferential treatment in favour of large companies [43].
this statement appears to be incompatible with the commission's position in previous fiscal aid cases stipulating that nothing justified preferential treatment in favour of large companies [43].

at indsende den endelige study report fra den kliniske undersøgelse (ror104836), “ a randomised, double- blind, placebo- controlled, parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound for a further 40 weeks open label extension treatment period in subjects suffering from moderate to severe restless legs syndrome. ” undersøgelsen forventes at starte i februar 2006.
esitada kliinilise uuringu (ror104836) „ randomiseeritud, topeltpime, platseebokontrolliga, paralleelgruppides uuring, et hinnata 26 nädalat kestva ropiniroolravi efektiivsust ja ohutust ning täiendavalt hinnata augmentatsiooni ja tagasilöögifenomeni esinemissagedust täiendava 40- nädalase avatud raviperioodi vältel patsientidel, kellel esineb mõõdukas kuni raske rahutute jalgade sündroom ” lõplik uuringuaruanne.